Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia
sotorasibNo engagement yet
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
sotorasib
5 people · 5 posts
First-generation G12C drugs (sotorasib, adagrasib) bind KRAS in the off state.
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
- zoldonrasibORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Floor
clinicaltrials.govScore2525
medRxiv OncologyScore3636 Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic review and meta-analysis
A systematic review and meta-analysis found that prior ICI exposure was associated with higher risk of severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer (13.2% vs 4.4%, RR 3.00, 95% CI 1.76-5.10), but matched analyses detected no difference at 6-week (RR 1.11) and 12-week (RR 1.08) intervals.
x.com@Score6060 x.com@Score6060
The Innovation | Medicine@Innov_MedicineScore6060